111523-41-2

Basic information

• Product Name: ENLOPLATIN
• Synonyms: ENLOPLATIN;platinum, (1,1-cyclobutanedicarboxylato(2-))(tetrahydro-4h-pyran-4,4-dimethanam (sp-4-2)-ine-n cis-(1,1-cyclobutanedicarboxylato)(tetrahydro-4h-pyran-4,4-bis(methylami ne)) platinum cl 287110 enloplatin;(SP-4-2)-[1，1-Cyclobumnedicarboxylato(2-)](tetrahydro-4H-pyran-4,4-dimethanamine-N，N’)platinum;CL-287110
• CAS NO: 111523-41-2
• Molecular Formula: C13H22N2O5Pt
• Molecular Weight: 481.4
• Mol File: 111523-41-2.mol
• Article Data: 1

Chemical Properties

• Melting Point: 260-263 °C (decomp)
• Boiling Point: 241°C at 760 mmHg
• Flash Point: 105.5°C
• Appearance: /
• Vapor Pressure: 0.0368mmHg at 25°C
• CAS DataBase Reference: ENLOPLATIN(CAS DataBase Reference)
• NIST Chemistry Reference: ENLOPLATIN(111523-41-2)
• EPA Substance Registry System: ENLOPLATIN(111523-41-2)

Safety Data

• Hazardous Substances Data: 111523-41-2(Hazardous Substances Data)

Usage

Uses

Antineoplastic.

InChI:InChI=1/C7H16N2O.C6H8O4.Pt/c8-5-7(6-9)1-3-10-4-2-7;7-4(8)6(5(9)10)2-1-3-6;/h1-6,8-9H2;1-3H2,(H,7,8)(H,9,10);/q;;+2/p-2

Upstream product

• 187224-67-5 {1,1-cyclobutanedicarboxylato^(2-)-O,O'}bis{sulfinylbis{methane}-S-}platinum(II) 

Related news

Analysis of ENLOPLATIN (cas 111523-41-2) by liquid chromatography and of platinum by atomic absorption spectrometry in various biological fluids09/01/2019

Analytical methods were developed and validated for the determination of enloplatin (an anticancer agent) in plasma by reversed-phase LC and for platinum (an elemental component of enloplatin) in plasma, plasma ultrafiltrate (PUF) and whole blood by flameless atomic absorption spectrometry (FAAS...detailed

Relevant articles and documents

(Malonato)bis[sulfinylbis[methane]-S]platinum(II) compounds: Versatile synthons for a new general synthesis of antitumor symmetrical and dissymmetrical (malonato)platinum(II) complexes

New (malonato)platinum(II) compounds, cis-[Pt(OOCACOO)(Me2SO)2] (A = CH2, cycloalkyl), have been prepared, and their reactions with various amines have led to a new general synthesis of antitumor symmetrical and dissymmetrical (malonato)platinum(II) complexes. Reaction of trans-(-)-1,2-cyclohexanediamine (CHDA*) with the cyclobutanedicarboxylate (CBDC) complex cis-[Pt(CBDC)(Me2SO)2] has been studied in detail, and crystallographic molecular structure determinations have been carried out on the Pt(CHDA*)(Me2SO)(CBDC) intermediate and the Pt(CHDA*)(CBDC) product. Crystals of Pt(CHDA*)(Me2SO)(CBDC) grown from aqueous solution form as unstable hydrates, which rapidly lose water molecules of crystallization upon removal from the crystallization solution at room temperature. X-ray data were collected on a crystal at -100° C. The complex crystallizes in the noncentrosymmetric triclinic unit cell P1 with four independent Pt(CHDA*)(Me2SO)(CBDC) molecules and thirteen independent water molecules per unit cell. Unit cell dimensions are a = 10.998 (3) A?, b = 13.946 (5) A?, c = 15.163 (5) A?, α = 65.39 (2)°, β = 88.21 (2)°, γ = 79.64 (2)°, and V = 2078 (1) A?3. Complex molecules form as two independent hydrogen-bonded dimers, [Pt(CHDA*)(Me2SO)(CBDC)]2, with hydrogen-bonded water molecules linking the two complex units. Platinum atoms of the complex are four-coordinate, bonded to the two nitrogens of the CHDA* ligand, the sulfur atom of the DMSO ligand, and one of the carboxylate oxygen atoms of the monodentate CBDC ligand. Crystals of Pt(CHDA*)(CBDC) obtained from aqueous solution form as hydrates in the noncentrosymmetric centered monoclinic unit cell C2. Unit cell dimensions are a = 24.889 (16) A?, b = 5.382 (2) A?, c = 11.426 (4) A?, β = 106.97 (2)°, and V = 1464 (1) A?3, with one independent complex molecule and two half water molecules per asymmetric region of the unit cell. Displacement of the DMSO ligand of Pt(CHDA*)(Me2SO)(CBDC) results in chelation of the CBDC ligand in Pt(CHDA*)(CBDC). The two half water solvate molecules are hydrogen bonded to oxygen atoms of adjacent complex molecules.